Understanding FAM222B: A Potential Drug Target and Biomarker (G55731)

Target Name: FAM222B

NCBI ID: G55731

FAM222B

Understanding FAM222B: A Potential Drug Target and Biomarker

FAM222B (FLJ10700) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the FAM (fucosin) family of proteins, which are known for their role in cell-signaling processes. FAM222B is also known as FLJ10700, which is a potential drug target (or biomarker) that has been identified using various techniques, including RNA sequencing and yeast two-hybrid assays.

The FAM222B protein is composed of 215 amino acid residues and has a calculated molecular mass of 33.9 kDa. It is expressed in a variety of tissues, including the brain, heart, liver, and pancreas, and is also found in the placenta and testes. FAM222B is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the protein(s) endoplasmic reticulum (ER-associated protein) subcellular localization scale (PLS) in a ratio of 1:1.03.

One of the unique features of FAM222B is its ability to interact with various molecules, including transcription factors, DNA-binding proteins, and protein(s) that are involved in cell signaling pathways. This interaction with other molecules suggests that FAM222B may play a role in intracellular signaling processes.

FAM222B has also been shown to interact with various protein(s) involved in cell signaling pathways, including but not limited to:

* NF-kappa-B signaling pathway: FAM222B has been shown to interact with the protein(s) p62 and p100, which are involved in the NF-kappa-B signaling pathway.
* PI3K/AKT signaling pathway: FAM222B has been shown to interact with the protein(s) p110 and p112, which are involved in the PI3K/AKT signaling pathway.
* TGF-β signaling pathway: FAM222B has been shown to interact with the protein(s) Smad4 and Syk, which are involved in the TGF-β signaling pathway.

These interactions suggest that FAM222B may play a role in intracellular signaling processes that are important for various cellular processes, including but not limited to cell growth, apoptosis, and inflammation.

In addition to its potential role in intracellular signaling processes, FAM222B has also been shown to have several potential drug target(s). For example, FAM222B has been shown to interact with various proteins involved in cell signaling pathways, including transcription factors, DNA-binding proteins, and protein(s) that are involved in cell signaling pathways. These interactions suggest that FAM222B may play a role in the regulation of cellular processes, including but not limited to cell growth, apoptosis, and inflammation.

FAM222B may also be a potential biomarker for various diseases, including but not limited to cancer, neurodegenerative diseases, and autoimmune diseases. This is because FAM222B is expressed in various tissues of the body, including those of the brain, heart, liver, and pancreas, which are involved in the development and progression of these diseases.

In conclusion, FAM222B is a protein that is expressed in various tissues of the body and is involved in the regulation of intracellular signaling processes. Its potential drug target(s) and biomarker status make it an attractive target for further study. Further research, including but not limited to yeast two-hybrid assays and RNA sequencing, is needed to fully understand the role of FAM222B in intracellular signaling processes and its potential as a drug target

Protein Name: Family With Sequence Similarity 222 Member B

The "FAM222B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM222B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets